8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Apr 9, 2026·SEC
Invivyd, Inc.(IVVD)Earnings, Financials & Key Ratios
IVVD•NASDAQ
Price updated Jun 11, 2026
AboutAdagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.Show more
- Revenue$53M+110.5%
- EBITDA-$53M+69.2%
- Net Income-$52M+69.1%
- EPS (Diluted)-0.30+79.0%
- Gross Margin92.99%-0.7%
- EBITDA Margin-100.05%+85.4%
- Operating Margin-103.99%+85.1%
- Net Margin-98.25%+85.3%
- ROE-33.96%+75.5%
- ROIC-494.92%
- Debt/Equity0.01-46.5%
IVVD Key Insights
Invivyd, Inc. (IVVD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 13 (bottom 13%)
- ✗Shares diluted 45.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IVVD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IVVD Price & Volume
Invivyd, Inc. (IVVD) stock price & volume — 10-year historical chart
Loading chart...
IVVD Growth Metrics
Invivyd, Inc. (IVVD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM52.27%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM45.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM68.81%
Return on Capital
10 Years-81.44%
5 Years-76.25%
3 Years-86.2%
Last Year-35.82%
IVVD Recent Earnings
Invivyd, Inc. (IVVD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 14, 2026EPS
$0.13
Est $0.08
-62.5%
Revenue
$14M
Est $18M
-23.8%
Q2 2026
Mar 5, 2026EPS
$0.02
Est $0.06
+133.3%
Revenue
$17M
Est $17M
+0.0%
Q4 2025
Nov 6, 2025EPS
$0.06
Est $0.05
-20.0%
Revenue
$13M
Est $16M
-15.4%
Q3 2025
Aug 14, 2025EPS
$0.12
Est $0.04
-200.0%
Revenue
$12M
Est $29M
-59.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.13vs $0.08-62.5% | $14Mvs $18M-23.8% |
| Q2 2026 | Mar 5, 2026 | $0.02vs $0.06+133.3% | $17Mvs $17M+0.0% |
| Q4 2025 | Nov 6, 2025 | $0.06vs $0.05-20.0% | $13Mvs $16M-15.4% |
| Q3 2025 | Aug 14, 2025 | $0.12vs $0.04-200.0% | $12Mvs $29M-59.4% |
Based on last 12 quarters of dataView full earnings history →
IVVD Peer Comparison
Invivyd, Inc. (IVVD) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REGN | 63.53B | 611.48 | 14.74 | 0.99% | 29.65% | 14.32% | 0.09 | |
 VRTX | 113.2B | 445.04 | 29.05 | 9.57% | 35.4% | 23.93% | 0.21 | |
 MNKD | 1.16B | 3.75 | 187.50 | 22.23% | -6.63% | |||
 ADMA | 1.93B | 8.32 | 13.87 | 19.63% | 32.43% | 38.97% | 0.17 | |
 SABS | 181.03M | 3.38 | -4.28 | -100% | -0.29% | 0.04 | ||
 ABBV | 397.56B | 224.77 | 94.84 | 8.57% | 6.91% | 62.15% | ||
 LLY | 1.1T | 1160.95 | 50.59 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ALNY | 38.61B | 289.39 | 124.20 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare IVVD vs Peers
Invivyd, Inc. (IVVD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IVVD Income Statement
Invivyd, Inc. (IVVD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 25.38M | 53.43M | 55.87M |
Revenue Growth % | - | - | - | - | - | 110.47% | 52.27% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 1.62M | 3.75M | 4.46M |
COGS % of Revenue | - | - | - | - | 6.37% | 7.01% | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 23.77M▲ 0% | 49.68M▲ 109.0% | 51.41M▲ 0% |
Gross Margin % | - | - | - | - | 93.63% | 92.99% | 92.02% |
Gross Profit Growth % | - | - | - | - | - | 109.03% | - |
Operating Expenses | 111.99M | 226.91M | 248.03M | 212.76M | 200.64M | 105.24M | 133.18M |
OpEx % of Revenue | - | - | - | - | 790.43% | 196.98% | - |
Selling, General & Admin | 0 | 36.52M | 47.04M | 49.13M | 63.39M | 66.93M | 74.78M |
SG&A % of Revenue | - | - | - | - | 249.72% | 125.28% | - |
Research & Development | 106.49M | 182.89M | 179.21M | 158.66M | 137.25M | 38.31M | 58.4M |
R&D % of Revenue | - | - | - | - | 540.71% | 71.7% | - |
Other Operating Expenses | 5.5M | 7.5M | 21.77M | 4.97M | 0 | 0 | 0 |
Operating Income | -111.99M▲ 0% | -226.91M▼ 102.6% | -248.03M▼ 9.3% | -212.76M▲ 14.2% | -176.88M▲ 16.9% | -55.56M▲ 68.6% | -81.77M▲ 0% |
Operating Margin % | - | - | - | - | -696.8% | -103.99% | -146.38% |
Operating Income Growth % | - | -102.62% | -9.31% | 14.22% | 16.87% | 68.59% | - |
EBITDA | -68.79M | -226.91M | -247.57M | -210.73M | -173.76M | -53.45M | -79.89M |
EBITDA Margin % | - | - | - | - | -684.54% | -100.05% | -143.01% |
EBITDA Growth % | - | -229.88% | -9.11% | 14.88% | 17.54% | 69.24% | 44.67% |
D&A (Non-Cash Add-back) | 43.2M | 1K | 462K | 2.03M | 3.11M | 2.11M | 1.88M |
EBIT | -43.2M | -219.41M | -226.26M | -207.78M | -176.88M | -55.56M | -81.22M |
Net Interest Income | 8K | 0 | -36.37M | 0 | 6.95M | 0 | 3.62M |
Interest Income | 8K | 0 | 6.71M | 0 | 6.95M | 0 | 3.62M |
Interest Expense | 0 | 0 | 43.08M | 0 | 0 | 0 | 0 |
Other Income/Expense | 13.71K | 118K | 6.71M | 14.12M | 6.95M | 3.07M | 4.17M |
Pretax Income | -111.98M▲ 0% | -226.79M▼ 102.5% | -241.32M▼ 6.4% | -198.64M▲ 17.7% | -169.93M▲ 14.5% | -52.49M▲ 69.1% | -77.6M▲ 0% |
Pretax Margin % | - | - | - | - | -669.42% | -98.25% | -138.9% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -111.98M▲ 0% | -226.79M▼ 102.5% | -241.32M▼ 6.4% | -198.64M▲ 17.7% | -169.93M▲ 14.5% | -52.49M▲ 69.1% | -77.6M▲ 0% |
Net Margin % | - | - | - | - | -669.42% | -98.25% | -138.9% |
Net Income Growth % | - | -102.54% | -6.41% | 17.68% | 14.46% | 69.11% | 45.63% |
Net Income (Continuing) | -111.98M | -226.79M | -241.32M | -198.64M | -169.93M | -52.49M | -77.6M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.59▲ 0% | -2.11▼ 257.6% | -2.17▼ 2.8% | -1.81▲ 16.6% | -1.43▲ 21.0% | -0.30▲ 79.0% | -0.25▲ 0% |
EPS Growth % | - | -257.63% | -2.84% | 16.59% | 20.99% | 79.02% | 68.81% |
EPS (Basic) | -0.59 | -2.11 | -2.17 | -1.81 | -1.43 | -0.30 | - |
Diluted Shares Outstanding | 111.25M | 110.78M | 108.27M | 109.53M | 118.56M | 172.21M | 309.67M |
Basic Shares Outstanding | 111.25M | 110.78M | 108.27M | 109.53M | 118.56M | 172.21M | 309.67M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
IVVD Balance Sheet
Invivyd, Inc. (IVVD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 117.38M | 616.71M | 376.92M | 224.88M | 100.68M | 247.47M | 204.91M |
Cash & Short-Term Investments | 114.99M | 591.42M | 371.99M | 200.64M | 69.35M | 226.69M | 184.15M |
Cash Only | 114.99M | 542.22M | 92.08M | 200.64M | 69.35M | 226.69M | 184.15M |
Short-Term Investments | 0 | 49.19M | 279.92M | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 229K | 377K | 933K | 11.17M | 13.92M | 11.65M |
Days Sales Outstanding | - | - | - | - | 160.6 | 95.09 | 72.24 |
Inventory | 0 | 0 | 0 | 0 | 0 | 25.5M | 25.45M |
Days Inventory Outstanding | - | - | - | - | - | 2.48K | 1.05K |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | -23.11M | -16.34M |
Total Non-Current Assets | 0 | 3.38M | 6.25M | 4.3M | 28.83M | 29.42M | 36.83M |
Property, Plant & Equipment | 0 | 83K | 6.06M | 4.13M | 2.89M | 3.81M | 10.22M |
Fixed Asset Turnover | - | - | - | - | 8.77x | 14.03x | 9.97x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 3.3M | 191K | 175K | 25.94M | 25.61M | 26.61M |
Total Assets | 117.38M▲ 0% | 620.09M▲ 428.3% | 383.17M▼ 38.2% | 229.18M▼ 40.2% | 129.51M▼ 43.5% | 276.88M▲ 113.8% | 241.74M▲ 0% |
Asset Turnover | - | - | - | - | 0.20x | 0.19x | 0.30x |
Asset Growth % | - | 428.27% | -38.21% | -40.19% | -43.49% | 113.78% | 183.01% |
Total Current Liabilities | 13.07M | 62.06M | 25.03M | 50.29M | 61.98M | 34.16M | 31.66M |
Accounts Payable | 8.15M | 5.78M | 1.52M | 7.95M | 10.45M | 13.74M | 2.02M |
Days Payables Outstanding | - | - | - | - | 2.36K | 1.34K | 1.06K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 1.31M | 1.59M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 794K | 4.95M | 6.03M | 10.79M | 3.94M | 19.11M | 28.04M |
Current Ratio | 8.98x | 9.94x | 15.06x | 4.47x | 1.62x | 7.24x | 6.47x |
Quick Ratio | 8.98x | 9.94x | 15.06x | 4.47x | 1.62x | 6.50x | 5.67x |
Cash Conversion Cycle | - | - | - | - | - | 1.24K | 61.27 |
Total Non-Current Liabilities | 169.56M | 12K | 2.17M | 1.42M | 0 | 1.18M | 7.03M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 1.18M | 7.03M |
Capital Lease Obligations | 0 | 0 | 2.17M | 722K | 0 | 0 | 3.49M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 169.56M | 12K | 1K | 700K | 0 | 0 | 0 |
Total Liabilities | 182.63M | 62.07M | 27.2M | 51.71M | 61.98M | 35.34M | 38.69M |
Total Debt | 0 | 0 | 3.72M | 2.17M | 1.3M | 2.49M | 8.63M |
Net Debt | -114.99M | -542.22M | -88.35M | -198.48M | -68.05M | -224.19M | -175.53M |
Debt / Equity | - | - | 0.01x | 0.01x | 0.02x | 0.01x | 0.04x |
Debt / EBITDA | - | - | - | - | - | - | -0.11x |
Net Debt / EBITDA | - | - | - | - | - | - | 2.20x |
Interest Coverage | - | - | -5.25x | - | - | - | - |
Total Equity | -65.25M▲ 0% | 558.02M▲ 955.2% | 355.97M▼ 36.2% | 177.47M▼ 50.1% | 67.54M▼ 61.9% | 241.54M▲ 257.6% | 203.05M▲ 0% |
Equity Growth % | - | 955.21% | -36.21% | -50.15% | -61.94% | 257.63% | 474.95% |
Book Value per Share | -0.59 | 5.04 | 3.29 | 1.62 | 0.57 | 1.40 | 0.66 |
Total Shareholders' Equity | -65.25M | 558.02M | 355.97M | 177.47M | 67.54M | 241.54M | 203.05M |
Common Stock | 1K | 11K | 11K | 11K | 12K | 28K | 28K |
Retained Earnings | -65.32M | -292.11M | -533.43M | -732.07M | -901.99M | -954.48M | -995.88M |
Treasury Stock | -85K | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -8K | -272K | -13K | -5K | -41K | -37K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IVVD Cash Flow Statement
Invivyd, Inc. (IVVD) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -14.57M | -184.74M | -219.99M | -173.16M | -170.49M | -58.13M | -78.72M |
Operating CF Margin % | - | - | - | - | -671.65% | -108.81% | - |
Operating CF Growth % | - | -1167.83% | -19.08% | 21.28% | 1.54% | 65.9% | 109.43% |
Net Income | -65.32M | -226.79M | -241.32M | -198.64M | -169.93M | -52.49M | -77.6M |
Depreciation & Amortization | 0 | 1K | 462K | 2.03M | 3.11M | 2.11M | 1.88M |
Stock-Based Compensation | 0 | 17.76M | 21.65M | 18.68M | 19.79M | 11.64M | 8.82M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 40.07M | 1.5M | 15.35M | -1.12M | 0 | 298K | 3.05M |
Working Capital Changes | 10.68M | 22.79M | -16.13M | 5.89M | -23.47M | -19.69M | -14.87M |
Change in Receivables | 0 | 0 | 0 | 0 | -10.91M | -3.34M | -3.46M |
Change in Inventory | 0 | 0 | 0 | 0 | -24.89M | -373K | -268K |
Change in Payables | 0 | -2.37M | -4.3M | 6.47M | 2.42M | 3.21M | -6.72M |
Cash from Investing | 0 | -50.71M | -230.67M | 280.68M | -140K | -155K | -737K |
Capital Expenditures | 0 | -84K | -1.71M | -615K | -140K | -155K | -737K |
CapEx % of Revenue | - | - | - | - | 0.55% | 0.29% | 1.32% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 129.56M | 662.68M | 506K | 1.04M | 39.33M | 215.63M | 215.52M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 129.56M | 666.07M | -4K | -1K | 39.28M | 215.63M | 215.74M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -3K | 0 | -4K | -1K | 0 | 0 | 0 |
Other Financing | 0 | -3.38M | 510K | 1.05M | 46K | 0 | -220K |
Net Change in Cash | 114.99M▲ 0% | 427.24M▲ 271.5% | -450.15M▼ 205.4% | 108.56M▲ 124.1% | -131.29M▼ 220.9% | 157.34M▲ 219.8% | 136.07M▲ 0% |
Free Cash Flow | -14.57M▲ 0% | -184.82M▼ 1168.4% | -221.69M▼ 20.0% | -173.78M▲ 21.6% | -170.63M▲ 1.8% | -58.29M▲ 65.8% | -79.45M▲ 0% |
FCF Margin % | - | - | - | - | -672.2% | -109.1% | -142.22% |
FCF Growth % | - | -1168.41% | -19.95% | 21.61% | 1.81% | 65.84% | 43.87% |
FCF per Share | -0.13 | -1.67 | -2.05 | -1.59 | -1.44 | -0.34 | -0.26 |
FCF Conversion (FCF/Net Income) | 0.13x | 0.81x | 0.91x | 0.87x | 1.00x | 1.11x | 1.02x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IVVD Key Ratios
Invivyd, Inc. (IVVD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -92.05% | -52.81% | -74.48% | -138.71% | -33.96% | -53.48% |
| Return on Invested Capital (ROIC) | - | -131.27% | -129.41% | - | -494.92% | -368.93% |
| Gross Margin | - | - | - | 93.63% | 92.99% | 92.02% |
| Net Margin | - | - | - | -669.42% | -98.25% | -138.9% |
| Debt / Equity | - | 0.01x | 0.01x | 0.02x | 0.01x | 0.04x |
| Interest Coverage | - | -5.25x | - | - | - | - |
| FCF Conversion | 0.81x | 0.91x | 0.87x | 1.00x | 1.11x | 1.02x |
| Revenue Growth | - | - | - | - | 110.47% | 52.27% |
Related:IVVD Dividend History·IVVD Revenue History·IVVD Price History·IVVD P/E History·IVVD Financial Ratios·IVVD Institutional Holders
IVVD SEC Filings & Documents
Invivyd, Inc. (IVVD) SEC filings — annual & quarterly reports (10-K, 10-Q)
IVVD Frequently Asked Questions
Invivyd, Inc. (IVVD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Invivyd, Inc. (IVVD) reported $55.9M in revenue for fiscal year 2025.
Invivyd, Inc. (IVVD) grew revenue by 110.5% over the past year. This is strong growth.
Invivyd, Inc. (IVVD) reported a net loss of $77.6M for fiscal year 2025.
Dividend & Returns
Invivyd, Inc. (IVVD) has a return on equity (ROE) of -34.0%. Negative ROE indicates the company is unprofitable.
Invivyd, Inc. (IVVD) had negative free cash flow of $79.5M in fiscal year 2025, likely due to heavy capital investments.